Drug-to-Antibody Ratio Estimation via Proteoform Peak Integration in the Analysis of Antibody-Oligonucleotide Conjugates with Orbitrap Fourier Transform Mass Spectrometry
| Autor: | Victor J Nesatyy, Anton N. Kozhinov, Pasi Virta, Konstantin O. Nagornov, Natalia Gasilova, Yury O. Tsybin, Patrik Holm, Laure Menin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Immunoconjugates
Resolution (mass spectrometry) Oligonucleotides deconvolution Orbitrap 01 natural sciences Fourier transform ion cyclotron resonance Mass Spectrometry Analytical Chemistry law.invention 03 medical and health sciences law Truncation (statistics) 030304 developmental biology 0303 health sciences Chromatography Fourier Analysis Oligonucleotide Chemistry 010401 analytical chemistry resolution ms mobility 0104 chemical sciences Pharmaceutical Preparations strategies Mass spectrum ions Deconvolution Conjugate |
| Zdroj: | Analytical chemistry. 93(38) |
| ISSN: | 1520-6882 |
| Popis: | The therapeutic efficacy and pharmacokinetics of antibody-drug conjugates (ADCs) in general, and antibody-oligonucleotide conjugates (AOCs) in particular, depend on the drug-to-antibody ratio (DAR) distribution and average value. The DAR is considered a critical quality attribute, and information pertaining to it needs to be gathered during ADC/AOC development, production, and storage. However, because of the high structural complexity of ADC/AOC samples, particularly in the initial drug-development stages, the application of the current state-of-the-art mass spectrometric approaches can be limited for DAR analysis. Here, we demonstrate a novel approach for the analysis of complex ADC/AOC samples, following native size-exclusion chromatography Orbitrap Fourier transform mass spectrometry (FTMS). The approach is based on the integration of the proteoform-level mass spectral peaks in order to provide an estimate of the DAR distribution and its average value with less than 10% error. The peak integration is performed via a truncation of the Orbitrap's unreduced time-domain ion signals (transients) before mass spectra generation via FT processing. Transient recording and processing are undertaken using an external data acquisition system, FTMS Booster X2, coupled to a Q Exactive HF Orbitrap FTMS instrument. This approach has been applied to the analysis of whole and subunit-level trastuzumab conjugates with oligonucleotides. The obtained results indicate that ADC/AOC sample purification or simplification procedures, for example, deglycosylation, could be omitted or minimized prior to the DAR analysis, streamlining the drug-development process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|